Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

PMID:
30285218
2.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv268-iv269. doi: 10.1093/annonc/mdy321. No abstract available.

PMID:
30285214
3.

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.

de Jong Y, Monderer D, Brandinelli E, Monchanin M, van den Akker BE, van Oosterwijk JG, Blay JY, Dutour A, Bovée JVMG.

Oncogenesis. 2018 Sep 21;7(9):74. doi: 10.1038/s41389-018-0084-0.

4.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv267. doi: 10.1093/annonc/mdy320. No abstract available.

PMID:
30188977
5.

Jason L. Hornick: Practical soft tissue pathology: a diagnostic approach, 2nd edition.

Bovée JVMG.

Virchows Arch. 2018 Aug 29. doi: 10.1007/s00428-018-2440-z. [Epub ahead of print] No abstract available.

PMID:
30159597
6.

Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis.

Song W, van den Berg E, Kwee TC, Jutte PC, Cleton-Jansen AM, Bovée JVMG, Suurmeijer AJ.

Clin Sarcoma Res. 2018 Aug 23;8:16. doi: 10.1186/s13569-018-0104-z. eCollection 2018.

7.

Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?

Mastboom MJL, Hoek DM, Bovée JVMG, van de Sande MAJ, Szuhai K.

Histopathology. 2018 Aug 28. doi: 10.1111/his.13744. [Epub ahead of print]

PMID:
30152874
8.

Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing.

Lam SW, Cleton-Jansen AM, Cleven AHG, Ruano D, van Wezel T, Szuhai K, Bovée JVMG.

J Mol Diagn. 2018 Sep;20(5):653-663. doi: 10.1016/j.jmoldx.2018.05.007. Epub 2018 Aug 20.

PMID:
30139549
9.

Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.

van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME, Bovée JVMG, Gelderblom H.

Oncologist. 2018 Aug 6. pii: theoncologist.2017-0574. doi: 10.1634/theoncologist.2017-0574. [Epub ahead of print]

PMID:
30082492
10.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.

van Broekhoven DLM, Verschoor AJ, van Dalen T, Grünhagen DJ, den Bakker MA, Gelderblom H, Bovee JVMG, Haas RLM, Bonenkamp HJ, van Coevorden F, Ten Oever D, van der Graaf WTA, Flucke UE, Pras E, Reyners AKL, Westermann AM, Oldenburger F, Verhoef C, Steeghs N.

Sarcoma. 2018 Jun 21;2018:5982575. doi: 10.1155/2018/5982575. eCollection 2018.

11.

Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study.

Verschoor AJ, Bovée JVMG, Mastboom MJL, Sander Dijkstra PD, Van De Sande MAJ, Gelderblom H.

Acta Orthop. 2018 Oct;89(5):570-574. doi: 10.1080/17453674.2018.1490987. Epub 2018 Jul 10.

12.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv68-iv78. doi: 10.1093/annonc/mdy095. No abstract available.

PMID:
29846513
13.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv51-iv67. doi: 10.1093/annonc/mdy096. No abstract available.

PMID:
29846498
14.

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink AB, van den Akker BEWM, Molenaar RJ, Cleton-Jansen AM, Bovée JVMG.

Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.

PMID:
29576625
15.

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG.

Clin Cancer Res. 2018 Jun 1;24(11):2678-2687. doi: 10.1158/1078-0432.CCR-17-3512. Epub 2018 Mar 6.

PMID:
29511030
16.

A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.

Verschoor AJ, Warmerdam FARM, Bosse T, Bovée JVMG, Gelderblom H.

BMC Cancer. 2018 Jan 22;18(1):92. doi: 10.1186/s12885-018-3999-0.

17.

The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.

Schaefer IM, Hornick JL, Bovée JVMG.

Lab Invest. 2018 Apr;98(4):414-426. doi: 10.1038/s41374-017-0003-6. Epub 2018 Jan 16. Review.

PMID:
29339836
18.

The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study.

Verschoor AJ, Bovée JVMG, Overbeek LIH; PALGA group, Hogendoorn PCW, Gelderblom H.

Virchows Arch. 2018 Feb;472(2):221-229. doi: 10.1007/s00428-017-2285-x. Epub 2018 Jan 8.

19.

Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.

Kostine M, Briaire-de Bruijn IH, Cleven AHG, Vervat C, Corver WE, Schilham MW, Van Beelen E, van Boven H, Haas RL, Italiano A, Cleton-Jansen AM, Bovée JVMG.

Oncoimmunology. 2017 Oct 26;7(2):e1386828. doi: 10.1080/2162402X.2017.1386828. eCollection 2018.

20.

Successful disinfection of femoral head bone graft using high hydrostatic pressure.

van de Sande MAJ, Bovée JVMG, van Domselaar M, van Wijk MJ, Sanders I, Kuijper E.

Cell Tissue Bank. 2018 Sep;19(3):333-340. doi: 10.1007/s10561-017-9678-6. Epub 2017 Dec 20.

21.

Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.

Veenstra R, Kostine M, Cleton-Jansen AM, de Miranda NF, Bovée JV.

Lab Invest. 2018 Jan;98(1):41-50. doi: 10.1038/labinvest.2017.128. Epub 2017 Nov 20.

PMID:
29155424
22.

Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis.

van IJzendoorn DGP, Forghany Z, Liebelt F, Vertegaal AC, Jochemsen AG, Bovée JVMG, Szuhai K, Baker DA.

J Biol Chem. 2017 Dec 29;292(52):21282-21290. doi: 10.1074/jbc.C117.815845. Epub 2017 Nov 17.

PMID:
29150442
23.

IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.

Martins-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen AM, Gomes CMF.

Cancer Lett. 2018 Feb 1;414:1-15. doi: 10.1016/j.canlet.2017.11.004. Epub 2017 Nov 8.

PMID:
29126913
24.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
25.

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.

PMID:
28860121
26.

Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia.

Majoor BC, Boyce AM, Bovée JV, Smit VT, Collins MT, Cleton-Jansen AM, Dekkers OM, Hamdy NA, Dijkstra PS, Appelman-Dijkstra NM.

J Bone Miner Res. 2018 Jan;33(1):84-90. doi: 10.1002/jbmr.3286. Epub 2017 Sep 20.

PMID:
28856726
27.

Molecular Pathology of Bone Tumors: What Have We Learned and How Does It Affect Daily Practice?

Bovée JVMG.

Surg Pathol Clin. 2017 Sep;10(3):xiii-xiv. doi: 10.1016/j.path.2017.06.001. No abstract available.

PMID:
28797513
28.

Vascular Tumors of Bone: The Evolvement of a Classification Based on Molecular Developments.

van IJzendoorn DGP, Bovée JVMG.

Surg Pathol Clin. 2017 Sep;10(3):621-635. doi: 10.1016/j.path.2017.04.003. Review.

PMID:
28797505
29.

Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.

de Andrea CE, San-Julian M, Bovée JVMG.

Surg Pathol Clin. 2017 Sep;10(3):537-552. doi: 10.1016/j.path.2017.04.005. Review.

PMID:
28797501
30.

Higher incidence rates than previously known in tenosynovial giant cell tumors.

Mastboom MJL, Verspoor FGM, Verschoor AJ, Uittenbogaard D, Nemeth B, Mastboom WJB, Bovée JVMG, Dijkstra PDS, Schreuder HWB, Gelderblom H, Van de Sande MAJ; TGCT study group.

Acta Orthop. 2017 Dec;88(6):688-694. doi: 10.1080/17453674.2017.1361126. Epub 2017 Aug 8.

31.

USP6 activation in nodular fasciitis by promoter-swapping gene fusions.

Patel NR, Chrisinger JSA, Demicco EG, Sarabia SF, Reuther J, Kumar E, Oliveira AM, Billings SD, Bovée JVMG, Roy A, Lazar AJ, Lopez-Terrada DH, Wang WL.

Mod Pathol. 2017 Nov;30(11):1577-1588. doi: 10.1038/modpathol.2017.78. Epub 2017 Jul 28.

32.

High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.

de Graaff MA, Malu S, Guardiola I, Kruisselbrink AB, de Jong Y, Corver WE, Gelderblom H, Hwu P, Nielsen TO, Lazar AJ, Somaiah N, Bovée JVMG.

Transl Oncol. 2017 Aug;10(4):546-554. doi: 10.1016/j.tranon.2017.05.007. Epub 2017 Jun 24.

33.

Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy.

de Groot S, Gelderblom H, Fiocco M, Bovée JV, van der Hoeven JJ, Pijl H, Kroep JR.

Onco Targets Ther. 2017 Jun 13;10:2963-2970. doi: 10.2147/OTT.S123726. eCollection 2017.

34.

Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases.

Bekers EM, Groenen PJTA, Verdijk MAJ, Raaijmakers-van Geloof WL, Roepman P, Vink R, Gilhuijs NDB, van Gorp JM, Bovée JVMG, Creytens DH, Flanagan AM, Suurmeijer AJH, Mentzel T, Arbajian E, Flucke U.

Genes Chromosomes Cancer. 2017 Oct;56(10):750-757. doi: 10.1002/gcc.22478. Epub 2017 Jul 25.

PMID:
28639284
35.

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Molenaar RJ, Coelen RJS, Khurshed M, Roos E, Caan MWA, van Linde ME, Kouwenhoven M, Bramer JAM, Bovée JVMG, Mathôt RA, Klümpen HJ, van Laarhoven HWM, van Noorden CJF, Vandertop WP, Gelderblom H, van Gulik TM, Wilmink JW.

BMJ Open. 2017 Jun 10;7(6):e014961. doi: 10.1136/bmjopen-2016-014961.

36.

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.

Cleven AHG, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM, Cleton-Jansen AM, Bovée JVMG.

Clin Sarcoma Res. 2017 May 4;7:8. doi: 10.1186/s13569-017-0074-6. eCollection 2017.

37.

Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics.

Ratcliffe P, Koivunen P, Myllyharju J, Ragoussis J, Bovée JV, Batinic-Haberle I, Vinatier C, Trichet V, Robriquet F, Oliver L, Gardie B.

Hypoxia (Auckl). 2017 Mar 15;5:11-20. doi: 10.2147/HP.S127042. eCollection 2017. Review.

38.

Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas.

Hoekstra AS, Hensen EF, Jordanova ES, Korpershoek E, van der Horst-Schrivers AN, Cornelisse C, Corssmit EP, Hes FJ, Jansen JC, Kunst HP, Timmers HJ, Bateman A, Eccles D, Bovée JV, Devilee P, Bayley JP.

Oncotarget. 2017 Feb 28;8(9):14525-14536. doi: 10.18632/oncotarget.14649.

39.

Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging.

Lou S, Balluff B, Cleven AHG, Bovée JVMG, McDonnell LA.

J Am Soc Mass Spectrom. 2017 Feb;28(2):376-383. doi: 10.1007/s13361-016-1544-4. Epub 2016 Nov 21.

40.

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.

Sundara YT, Kostine M, Cleven AH, Bovée JV, Schilham MW, Cleton-Jansen AM.

Cancer Immunol Immunother. 2017 Jan;66(1):119-128. doi: 10.1007/s00262-016-1925-3. Epub 2016 Nov 16.

41.

High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.

Lou S, Cleven AH, Balluff B, de Graaff M, Kostine M, Briaire-de Bruijn I, McDonnell LA, Bovée JV.

Clin Sarcoma Res. 2016 Oct 1;6:17. eCollection 2016.

42.

An experimental guideline for the analysis of histologically heterogeneous tumors by MALDI-TOF mass spectrometry imaging.

Lou S, Balluff B, Cleven AHG, Bovée JVMG, McDonnell LA.

Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):957-966. doi: 10.1016/j.bbapap.2016.09.020. Epub 2016 Oct 8.

PMID:
27725306
43.

Cutaneous nodular fasciitis with genetic analysis: a case series.

Kumar E, Patel NR, Demicco EG, Bovee JV, Olivera AM, Lopez-Terrada DH, Billings SD, Lazar AJ, Wang WL.

J Cutan Pathol. 2016 Dec;43(12):1143-1149. doi: 10.1111/cup.12828. Erratum in: J Cutan Pathol. 2017 May;44(5):512.

PMID:
27686647
44.

Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

de Jong Y, van Maldegem AM, Marino-Enriquez A, de Jong D, Suijker J, Briaire-de Bruijn IH, Kruisselbrink AB, Cleton-Jansen AM, Szuhai K, Gelderblom H, Fletcher JA, Bovée JV.

Lab Invest. 2016 Oct;96(10):1128-37. doi: 10.1038/labinvest.2016.91. Epub 2016 Sep 12.

45.

Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Cleven AH, Al Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV.

Mod Pathol. 2016 Sep;29(9):1113. doi: 10.1038/modpathol.2016.103. No abstract available.

46.

Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Mariño-Enríquez A, Bovée JV.

Surg Pathol Clin. 2016 Sep;9(3):457-73. doi: 10.1016/j.path.2016.04.009. Review.

47.

Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.

Boon E, van der Graaf WT, Gelderblom H, Tesselaar ME, van Es RJ, Oosting SF, de Bree R, van Meerten E, Hoeben A, Smeele LE, Willems SM, Witjes MJ, Buter J, Baatenburg de Jong RJ, Flucke UE, Peer PG, Bovée JV, Van Herpen CM.

Head Neck. 2017 Jan;39(1):140-146. doi: 10.1002/hed.24556. Epub 2016 Aug 10.

48.

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Peterse EF, Cleven AH, De Jong Y, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JV.

BMC Cancer. 2016 Jul 14;16:475. doi: 10.1186/s12885-016-2522-8.

49.

Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers.

Hoekstra AS, Addie RD, Ras C, Seifar RM, Ruivenkamp CA, Briaire-de Bruijn IH, Hes FJ, Jansen JC, Corssmit EP, Corver WE, Morreau H, Bovée JV, Bayley JP, Devilee P.

Hum Mol Genet. 2016 Sep 1;25(17):3715-3728. doi: 10.1093/hmg/ddw218. Epub 2016 Jul 8.

PMID:
27402879
50.

Multimodal Mass Spectrometry Imaging of N-Glycans and Proteins from the Same Tissue Section.

Heijs B, Holst S, Briaire-de Bruijn IH, van Pelt GW, de Ru AH, van Veelen PA, Drake RR, Mehta AS, Mesker WE, Tollenaar RA, Bovée JV, Wuhrer M, McDonnell LA.

Anal Chem. 2016 Aug 2;88(15):7745-53. doi: 10.1021/acs.analchem.6b01739. Epub 2016 Jul 14.

PMID:
27373711

Supplemental Content

Loading ...
Support Center